Transaction covers ImmunoGen’s huC242 antibody.

Laureate Pharma will provide manufacturing services for ImmunoGen’s huC242 antibody used in the production of their huC242-DM4 Tumor-Activated Prodrug (TAP) compound, now in Phase II testing.

“ImmunoGen is well known for its proprietary TAP technology, which uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells,” notes Robert J. Broeze, Ph.D., Laureate Pharma’s president and CEO.

“Laureate Pharma has an established track record in the manufacture of protein-based biopharmaceuticals,” adds Dr. Broeze.

Previous articleMutation Linked to Prostate Cancer in African Americans Discovered
Next articleDainippon Sumitomo Pharma Gains Japanese Rights to Neurocrine’s Insomnia Therapy in Deal Valued at over $30M